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Background: We have prospectively followed all adult St Jude Medical mechanical
valve recipients at the Medical University of South Carolina since the initial implant
in January 1979 and now present our 20-year experience.
Methods: We prospectively followed 837 valve recipients (aortic valve replacement;
n  478; mitral valve replacement; n  359) from January 1979 to December 2000
at 12-month intervals.
Results: Ages ranged from 19 to 84 years. Follow-up averaged (mean  standard
deviation) 7  5 years (98% complete). Patients were in New York Heart Associ-
ation class III or IV in 77% (aortic valve replacement) and 89% (mitral valve
replacement) preoperatively. A 19-mm valve was implanted in 15.5% of aortic
valve replacement patients. Coronary bypass was required in 31% of aortic valve
replacements and 20% of mitral valve replacements. Operative mortality was
17/478 (3.6%) in aortic valve replacement and 19/359 (5.3%) in mitral valve
replacement, and multivariable predictors were 19-mm valve size, 3 or more
coronary bypass grafts, and New York Heart Association class IV for aortic valve
replacement and New York Heart Association class IV and age for mitral valve
replacement. Actuarial survivorship at 10 and 20 years was 57%  3% and 26% 
5% for aortic valve replacement and 61%  3% and 39%  4% for mitral valve
replacement. Multivariable predictors of late death were African-American ethnic-
ity, New York Heart Association class III or IV, coronary bypass, and age for aortic
valve replacement and New York Heart Association class III or IV, coronary
bypass, and age for mitral valve replacement. For aortic valve replacement, effective
orifice area was univariately (P .002) but not multivariately (P .378) predictive
of late death. Structural valve deterioration was not observed. For aortic valve
replacement, actuarial freedom (at 10 and 20 years) from reoperation was 93% 
1% and 90%  2%; thromboembolism, 82%  3% and 68%  8%; bleeding
events, 77%  3% and 66%  6%; prosthetic valve endocarditis, 94%  1% and
94%  1%; valve-related mortality, 94%  2% and 86%  4%; and valve-related
mortality or morbidity, 58%  3% and 32%  8%. For mitral valve replacement,
actuarial freedom (at 10 and 20 years) from reoperation was 96%  1% and 90%
 3%; thromboembolism, 77%  3% and 59%  7%; bleeding events, 86%  2%
and 65%  8%; prosthetic valve endocarditis, 98%  1% and 96%  2%;
valve-related mortality, 89% 0.2% and 74% 8%; and valve-related mortality or
morbidity, 63%  3% and 29%  7%.
Conclusions: After 2 decades of observation with close follow-up, the St Jude
Medical mechanical valve continues to be a reliable prosthesis.
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The St Jude Medical mechanical valve pros-thesis (St Jude Medical Inc, St Paul, Minn)is a low-profile bileaflet mechanical valveconstructed of pyrolytic carbon. The centralflow design was originally believed to offera lower transvalvular gradient compared
with other mechanical valves, and its construction sug-
gested that it would be durable and thromboresistant. These
attributes have been largely substantiated by early, interme-
diate, and late reports of the use of this valve.1-10 Patients of
the Medical University of South Carolina who have under-
gone valve replacement with the St Jude Medical mechan-
ical prosthesis have been prospectively enrolled in an on-
going study since a clinical trial of this valve was initiated
in January of 1979. We have previously reported a 4-year,1
10-year,2 and 15-year7 experience in 1984, 1992, and 1999,
respectively. This report summarizes our 20-year experi-
ence with a consecutive series of recipients. During this
period, approximately 48% of the adults undergoing valve
replacement in our institution received tissue valves. This
report considers only adult patients who have undergone
isolated atrial valve replacement (AVR) or mitral valve
replacement (MVR) with or without coronary bypass graft-




Between January of 1979 and December of 2000, 837 patients
underwent either isolated AVR (478 patients) or MVR (359 pa-
tients) with the St Jude Medical mechanical valve prosthesis. The
preoperative and intraoperative characteristics of the AVR and
MVR cohorts are given in Table 1. All patients undergoing valve
replacement at the Medical University of South Carolina since
1979 were entered prospectively into a computer database and
were followed up on an annual basis either at this hospital or by the
referring physician. In addition, written questionnaires were sent
yearly to all patients. If the questionnaires were not returned or the
patient reported an adverse event for which further details were
required, telephone or personal interviews were conducted. Six-
teen patients were lost (11 AVR, 5 MVR); therefore, follow-up
was 98% complete overall. In the AVR group, follow-up was 98%
complete and ranged from 1 month to 21 years (mean 7 5 years),
representing a total of 3212 patient years. In the MVR group,
follow-up was 99% complete and ranged from 1 month to 20 years
(mean 7  6 years), representing a total of 2536 years. Morbidity
and mortality were stringently defined according to the published
guidelines of the Society of Thoracic Surgeons and The American
Association for Thoracic Surgery.11
Operative techniques were similar to those published in prior
reports.1,2,7 Briefly, standard cardiopulmonary bypass was estab-
lished using disposable bubble or membrane oxygenator and mod-
erate hypothermia (26°C to 32°C). Cold crystalloid or blood car-
dioplegia was used for myocardial protection according to surgeon
preference. An increasing tendency toward the use of retrograde
blood cardioplegia was observed in later years. After debriding the
valve annulus, the prosthesis was secured using interrupted sutures
of 2-O Dacron reinforced with Teflon pledgets. Sutures were
carefully placed from above and through the annulus so that the
valve annulus would be everted when the sutures were tied, thus
inserting the prosthesis in an intra-annular position. Beginning in
1988, the subvalvular apparatus of the mitral valve was preserved
whenever technically feasible. Valve sizes for the 2 groups ranged
from 19 to 33 mm (Table 1).
In the AVR group, the standard St Jude Medical mechanical
prosthesis was used in 378 patients. The Masters series valve was
used in 78 patients and the Hemodynamic plus valve was used in
22 patients. In the MVR group, the standard St Jude Medical
prosthesis was used in 266 patients and the Masters series valve
was used in 93 patients. Thirty-three patients received AVR with
valve sewing rings impregnated with Silzone, as did 37 patients
undergoing MVR.
TABLE 1. Patient demographics
Variable AVR MVR
Total number 478 359
Age (years)
Range 20-84 19-82
Mean  SD 56 15 53 13
Sex
Male 335 (70%) 145 (40%)
Female 143 (30%) 214 (60%)
Etiology
Rheumatic 73 (15%) 157 (44%)
Endocarditis 35 (7%) 23 (6%)
Calcific 248 (52%) 21 (6%)
Reoperative 34 (7%) 43 (12%)
Ischemic 0 (0%) 39 (11%)
Degenerative 44 (9%) 67 (19%)
Congenital 42 (9%) 6 (2%)
Other 2 (0.4%) 3 (1%)
Lesion
Stenosis 261 (55%) 97 (27%)
Insufficiency 154 (32%) 222 (62%)
Combined 63 (13%) 40 (11%)
Valve sizes (mm)
19 74 (16%) 0
21 123 (26%) 0
23 140 (29%) 3 (1%)
25 78 (16%) 8 (2%)
27 47 (10%) 49 (14%)
29 11 (2%) 134 (37%)
31 4 (0.8%) 104 (29%)
33 1 (0.2%) 61 (17%)
Associated CABG 150 (31%) 72 (20%)
Preoperative NYHA
class
I 24 (15%) 12 (3%)
II 85 (18%) 28 (8%)
III 236 (49%) 166 (46%)
IV 133 (28%) 153 (43%)
Operative mortality 17 (3.6%) 19 (5.3%)
Patient follow-up (years) 7 5 7 6
Lost to follow-up 11 (2%) 5 (1%)
NYHA, New York Heart Association; CABG, coronary artery bypass graft-
ing; SD, standard deviation.
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Heparin administration was started (5000 units subcutaneously
every 6-12 hours depending on the surgeon preference) on the first
postoperative day and continued until prothrombin time or more
recently the International Normalized Ratio (INR) was regulated
with the administration of warfarin sodium. Early in our experi-
ence, the INR was maintained at 2.5 to 3.5. More recently, we have
recommended a target INR of 2.0 for patients who have undergone
AVR and 2.0 to 2.5 for MVR. The warfarin dose was regulated by
the surgeon during hospitalization and during early follow-up and
thereafter by the referring physician.
Statistical Analysis
Continuous variables are reported as the mean  1 standard
deviation and the categorical variables are represented as percent-
ages. Actuarial curves were constructed to describe mortality and
the incidence of valve-related complications using the Kaplan-
Meier technique and are reported with the standard error of the
mean.12-14 Because actuarial analysis is known to overestimate the
incidence of nonfatal end points, “actual” or cumulative incidence
curves were constructed for both the AVR and MVR groups for
the end points of reoperation, endocarditis, thromboembolic
events, and anticoagulation-related hemorrhage.15 Linearized
rates, used to describe multiple events, were reported as %/patient-
year and those reported for the Silzone valve subset were com-
pared to the remainder of the valve cohort using the exact binomial
test. Independent factors associated with operative and late death
were identified using logistic regression16 and the Cox propor-
tional hazards regression model,17 respectively. Variables used for
both the AVR and MVR groups are summarized in the Appendix.
Effective orifice areas (EOAs) used for analysis were kindly pro-
vided by St Jude Medical, Inc.
Results
Survival
In the AVR cohort there were 17 operative and 173 late
deaths (37 valve-related, 63 cardiac, 44 noncardiac, 29
sudden/unknown). In the MVR group there were 19 oper-
ative and 117 late deaths (2 valve-related, 54 cardiac, and 64
noncardiac). Cox regression analysis showed that valve size
of 19 mm, coronary artery bypass grafting (CABG) of more
than 3 vessels, and New York Heart Association (NYHA)
class IV were independent predictors of operative death in
the AVR cohort. EOA and the EOA index did not emerge as
independent predictors of operative mortality. Preoperative
NYHA class IV and increased age were predictors for
operative death in the MVR cohort (Table 2). Actuarial
survivorship (Figure 1) at 10 and 20 years was 57%  3%
and 26%  5% (AVR) and 61%  3% and 39%  4%
(MVR). Cox analysis showed that independent predictors of
late death in the AVR group were African-American eth-
nicity, NYHA class III or IV, concomitant coronary bypass,
and increasing age. EOA was univariately (P  .002) but
not multivariately (P  .378) predictive of late death. In-
dependent predictors of late death following MVR were
NYHA class III or IV, concomitant CABG, and increased
age (Table 2).
Reoperation
Reoperation was performed for 29 patients in the AVR
cohort and 15 patients in the MVR cohort. Reasons for
reoperation in the AVR cohort were perivalvular dehiscence
in 5 patients, endocarditis in 19 patients, and other causes in
5. Reasons for reoperation in the MVR group were perival-
vular dehiscence in 7 patients, prosthetic valve endocarditis
in 6 patients, and other causes in 2 patients. Structural valve
deterioration was not seen in either the AVR or MVR group.
Actuarial and cumulative incidence freedom from reopera-
tion is given in Figure 2. In the AVR group, actuarial
freedom from reoperation was 93%  1% and 90%  2%
TABLE 2. Factors associated with operative and late death
Variable Univariate P value Multivariate P value Odds ratio 95% CL
Operative death
Aortic valve replacement
Valve size 19 mm .003 .041 3.81 1.36, 10.65
CABG  3 vessels .048 .041 3.55 1.06, 11.94
NYHA class IV .019 .039 2.86 1.05, 7.79
Mitral valve replacement
Preop NYHA class IV .005 .022 3.48 1.19, 10.14
Increased age .013 .039 1.05 1.00, 1.09
Late death
Aortic valve replacement
African-American race .023 .0005 2.49 1.73, 3.60
NYHA class III or IV .0005 .001 2.25 1.42, 3.55
Associated CABG .0005 .002 1.69 1.22, 2.33
Increased age .0005 .0005 1.04 1.03, 1.05
Mitral valve replacement
NYHA class III or IV .016 .015 3.04 1.24, 7.46
Associated CABG .001 .047 1.60 1.01, 2.55
Increased age .0005 .002 1.03 1.01, 1.04
NYHA, New York Heart Association; CABG, coronary artery bypass grafting.
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at 10 and 20 years. Actual freedom was 94% 1% and 92%
 1% at 10 and 20 years. In the MVR group actuarial
freedom from operation was 96%  1% and 90%  3% at
10 and 20 years. Cumulative incidence percentages were
95%  1% and 93%  2% at 10 and 20 years.
Thromboembolic Complications
In the AVR group, thromboembolism occurred in 54 pa-
tients (64 events total). Of these 33 were defined as strokes
(10 were fatal) and 21 as transient cerebral ischemic attacks.
Three patients had peripheral embolic events (1 was fatal)
and 7 patients had valve thrombosis (2 were fatal). Throm-
boembolism occurred in 61 patients in the MVR group (87
events total). Of these, 56 were defined as strokes (10 were
fatal) and 23 as transient ischemic attacks. Five patients had
peripheral embolic events and 3 patients had valve throm-
bosis.
Kaplan-Meier analysis showed the 10- and 20-year free-
dom from thromboembolic events to be 82%  3% and
68%  8% in the AVR group and 77%  3% and 59% 
Figure 1. Actuarial survival after AVR and MVR.
Figure 2. Actuarial and “actual” freedom from reoperation after AVR and MVR.
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7% in the MVR group. Cumulative incidence analysis
showed 10- and 20-year freedom from thromboembolic
events to be 86%  2% and 79%  3% in the AVR group
and 80%  3% and 71%  4% in the MVR group. Actu-
arial and cumulative incidence freedom from thromboem-
bolic events is shown in Figure 3.
Bleeding Events
Major bleeding events occurred in 80 patients in the AVR
group and 45 patients in the MVR group. Actuarial freedom
from bleeding complications was 77%  3% and 66% 
6% at 10 and 20 years in the AVR group and 86%  2%
and 65%  8% in the MVR group. Cumulative incidence
analysis showed freedom from bleeding events to be 80%
2% and 75%  3% in the AVR group at 10 and 20 years
and 87% 2% and 77% 4% in the MVR group at 10 and
20 years. Actuarial and cumulative incidence freedom from
bleeding events is shown in Figure 4.
Prosthetic Valve Endocarditis
Prosthetic valve endocarditis (PVE) occurred in 25 AVR
patients and 7 MVR patients. After 4 years of follow-up, no
cases of PVE were seen in the AVR group and only 2 cases
were seen in the MVR group. For AVR, actuarial and
cumulative incidence freedom from PVE was 94%  1%
and 94.3% at both 10 and 20 years. For MVR actuarial
freedom from PVE was 98%  1% and 96%  2% at 10
and 20 years (P  .02 from AVR), with cumulative inci-
dence estimates being 98% and 97% at 10 and 20 years.
Valve-Related Mortality
In the AVR cohort, 37 patients died of valve-related causes:
embolism in 11 patients, valve thrombosis in 2 patients,
bleeding events in 13 patients, prosthetic endocarditis in 6
patients, death related to reoperation for valve re-replace-
ment in 4 patients, and death related to catheterization for
perivalvular leak in 1 patient. In addition, 29 patients died of
unknown causes. In the MVR group, 21 patients died of
valve-related causes. These were due to embolism in 10
patients, bleeding events in 8 patients, prosthetic endocar-
ditis in 2 patients, and death related to reoperation for valve
re-replacement in 1 patient. Twelve patients died of un-
known causes.
Kaplan-Meier analysis showed freedom from valve-re-
lated deaths to be 94%  2% and 86%  4% at 10 and 20
years in the AVR group and 89%  2% and 74%  8% at
10 and 20 years in the MVR group. Actuarial freedom from
valve-related mortality is given in Figure 5.
Valve-Related Mortality or Morbidity
In the AVR cohort, 151 patients had valve-related morbidity
or death. At 10 and 20 years, freedom from valve-related
mortality or morbidity was 58%  3% and 32%  8%,
respectively. In the MVR group, 109 patients had valve-
related morbidity or death. At 10 and 20 years, freedom
from valve-related mortality or morbidity was 63%  3%
and 29%  7%, respectively. Freedom from valve-related
mortality or morbidity in the AVR and MVR groups is
given in Figure 5.
Valve Prostheses with Silzone-Impregnated Sewing
Rings
A total of 70 patients received valve prostheses with Sil-
zone-impregnated sewing rings between May 1998 and
December 1999 and were followed for a total of 111 pa-
tient-years. Analysis of the Silzone subset compared with
Figure 3. Actuarial and “actual” freedom from thromboembolic events after AVR and MVR.
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the remaining cohort of 767 patients (5638 patient-years)
showed a significantly higher incidence of prosthetic valve
endocarditis (2.7%/patient-year vs 0.5%/patient-year, P 
.02). All of these patients showed clinical and operative
findings of endocarditis but were culture-negative. There
were also nonsignificant trends toward increased reopera-
tion (2.7%/patient-year vs 0.7%/patient-year, P .053) and
late death (9.0%/patient-year vs 5.0%/patient-year, P 
0.08) in the Silzone subset.
Discussion
The St Jude Medical bileaflet, pyrolytic carbon mechanical
valve was introduced in 1977 and received approval from
the Food and Drug Administration in 1982. We started
using this valve while it was still an investigational device
because of concerns about the durability of porcine valves
and because of reports of structural complications in other
mechanical valves. Both in vitro and in vivo studies dem-
onstrated low gradients across the valve in both catheter-
Figure 4. Actuarial and “actual” freedom from bleeding events after AVR and MVR.
Figure 5. Actuarial and “actual” freedom from valve-related morbidity or mortality after AVR and MVR.
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ization and echocardiographic evaluations.18,19 In our pre-
vious reports,1,2,7 we have observed, as have others,8-10 that
the St Jude Medical mechanical prosthesis has superior
durability (we have observed no structural failures), excel-
lent hemodynamics, and a low incidence of thromboembo-
lism. The current study examines 20 years of follow-up and
reports our long-term experience with this valve. This data
in this series was updated prospectively on an annual basis,
which may result in a more complete account of complica-
tions due to better patient recall.
Operative mortality in the current series is 3.6% in the
AVR group and 5.3% in the MVR group. These results
compare favorably with other long-term studies of this
prosthesis.8-10 Our data continue to show that preoperative
patient characteristics such as age, previous valve replace-
ment, cardiac function, and coronary disease may have a
greater influence on operative mortality than the type of
valve prosthesis implanted. Similar operative mortality is
seen in other series of tissue and other commonly used
mechanical valves.20-23
As other studies have observed,8-10 our data show that
late death is usually unrelated to the prosthetic valve. Mul-
tivariable analysis demonstrated that the major independent
variables impacting the long-term outcome in this patient
population were high NYHA class, concomitant CABG,
and increasing age in the both the AVR and MVR groups.
In addition, in the AVR group African-American ethnicity
emerged as a strong predictor of outcome. The reason for
this is unclear. Previous studies have shown that African-
American ethnicity poses a significantly higher risk for
hypertension, diabetes mellitus, and renal disease.24-26 Sub-
group analysis within this cohort showed no significant
differences between African-American and other ethnic
groups with respect to these variables. Further analysis is
required to identify factors that influence this predictor of
outcome.
Thromboembolism remains a major complication after
mechanical valve replacement. The linearized rate of throm-
boembolic complications in this series (AVR 2.0%/patient-
year, MVR 3.4%/patient-year) is slightly lower than in our
last report. This may reflect improved ability to reach and
maintain acceptable anticoagulation status in our patients.
The incidence of thromboembolism is comparable with
other series of St Jude Medical mechanical valve replace-
ment (0.8% to 3.5%/patient-year).3-6,8-10 These thromboem-
bolic rates are also comparable with the composite rates for
other mechanical valves and tissue valves.20-22
The incidence of anticoagulation-related bleeding com-
plications has remained relatively low. The linearized rate
was 2.5%/patient-year (AVR) and 1.8%/patient-year
(MVR). This represents a considerable reduction in antico-
agulant-related bleeding compared with our original 5-year
study (AVR, 6.9%/patient-year; MVR, 2.4%/patient-year),1
a modest reduction compared with our 10-year report
(AVR, 3.5%/patient-year; MVR, 2.2%/patient-year),2 and
little difference from our 15-year report (AVR, 2.7%/pa-
tient-year; MVR, 1.6%/patient-year).7 Other investigators
have also observed a higher incidence of anticoagulation-
related bleeding after AVR compared with MVR.5 In gen-
eral, we have been impressed with the low thromboembolic
rate of the St Jude Medical mechanical prosthesis and have
gradually lowered our target INR from 2.5 to 3.5 to 2.0 to
2.5 as have other groups,27,28 and this may account for the
progressive decline in bleeding complications. Overall,
however, thromboembolic and bleeding complications con-
tinue to be the Achilles’ heel of mechanical valve replace-
ment, with cumulative yearly rates of 4.5% for AVR and
5.3% for MVR, accounting for most of the valve-related
morbidity seen in these patients.
The incidence of prosthetic valve endocarditis was quite
low (AVR, 0.8%/patient-year; MVR, 0.3%/patient-year)
and is similar to other series.8-10 It is interesting that after
approximately 5 years, there is near complete freedom from
endocarditis in both the aortic and mitral valve groups. It
has been speculated that valve design, increased probability
of prosthetic valve sterilization, and early incorporation of
the cloth sewing ring by tissue in growth may offer some
protection from late bacterial invasion.
Data from the 70 patients in this series who received
Silzone-treated valves showed a higher linearized rate of
prosthetic valve endocarditis. The association between Sil-
zone treatment and valve-related complications is somewhat
controversial but has been documented in other series.29-31
This valve was not used in our institution after December
1999 because of concerns regarding an increased rate of
endocarditis and valve dehiscence.
Long-term follow-up of these patients has confirmed that
undergoing prosthetic valve replacement does not confer a
survival rate like that of the general population. To justify
this within our data set, age-adjusted standard mortality
rates32 (SMR) were calculated for mitral and aortic valves
combined. The expected number of deaths was propagated
using the age-specific national death rates for the year
200033 and the number of corresponding at risk patient-
years for our valve population. Because the proportion of
males to females in our study differed from that of the
national population, a separate SMR was calculated for each
gender. The results showed that our valve population had
mortality rates significantly higher than those of the general
population (men, SMR 4.3; women, SMR 5.4; P  .0001).
Although 20-year freedom from valve-related complica-
tions was only 32% (AVR) and 29% (MVR), data from this
study and others6 suggest that overall long-term survival
after prosthetic valve replacement may be more strongly
influenced by preexisting comorbidities prior to surgery
than by the presence of a mechanical valve. As increasing
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numbers of elderly patients with more comorbidities un-
dergo valve replacement, the influence of valve-related fac-
tors on mortality rate is likely to continue to decline com-
pared with patient-related factors. In addition, with the
improved durability of later generation tissue valves, the
long-term results of mechanical valve replacement are also
likely to be affected by increased use of bioprosthetic valves
in younger patients.
In summary, this series of patients undergoing AVR and
MVR with the St Jude Medical mechanical prosthesis with
follow-up to 20 years confirms the excellent performance of
this valve that we have documented in our earlier reports. In
addition, the complete absence of structural valve deterio-
ration makes the St Jude Medical mechanical heart valve
prosthesis an excellent choice for patients who require me-
chanical prosthetic valve replacement.
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Discussion
Dr Alfredo Trento (Los Angeles, Calif). This is an important
retrospective review because it further conclusively supports with
a longer follow-up the data on the St Jude Medical valve, which I
think can be translated with minor differences to the other bileaflet
valves.
Two years ago we published our 20-year comparison between
St Jude Medical and tissue valves. There were 670 St Jude Medical
valves and 720 tissue valves in the aortic position, about 500 St
Jude Medical valves and 400 tissue valves in the mitral position.
The mean age of patients with the St Jude Medical valve was
almost 10 years greater. The 10- and 20-year actuarial survival for
all the patients with mechanical and biological prostheses was
similar to that presented here by you today.
Freedom from thromboembolic events was also similar for both
St Jude Medical and tissue valves in both aortic and mitral posi-
tion. Freedom from hemorrhage was also similar. The only differ-
ence is that in the aortic position, biological prostheses fared much
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better, with a freedom from hemorrhage of 94% and 92% at 10 and
20 years, respectively.
We have also learned from other retrospective studies, as well
from the 2 randomized studies that are published, that in general,
long-term survival is not influenced by the type of valve that we
use, mechanical or biologic, but by other factors, as you men-
tioned, like age, coronary artery disease, New York Heart Asso-
ciation class, diabetes, and finally, and probably, valve to patient
size mismatch.
In view of this background, justifiably or not, over the past 10
years, in the aortic position we have reduced the use of St Jude
Medical valves from 55% in 1991 to less than 20% in 2002. In the
mitral position the same things happened in favor of mitral valve
repair.
Quality of life, freedom from warfarin, and increased mobility
of the patient population, which makes follow-up more difficult,
have steered patients and physicians away from warfarin. Has your
experience been similar on the choice of valves? Could you also
relate the thromboembolic and hemorrhagic complications to the
patient’s INR when they happen? Was the patient’s INR out of
range?
Now, the most important issue is the warfarin therapy. How
low do you think you can push the INR? Do you think we can have
a safe anticoagulation for the aortic valve with an INR between 1.5
and 2 for the aortic position and an INR around 2 for the mitral
position? That would make warfarin therapy much more attractive.
Dr Ikonomidis (Charleston, SC). Thank you, Dr Trento, for
those insightful comments and questions. With regard to compar-
ing mechanical valves to tissue valves, what we have observed is
what has generally been observed in most studies, namely that the
durability of mechanical valves exceeds that of tissue valves,
whereas tissue valves show superior freedom from thromboem-
bolic and bleeding complications.
As far as relating thromboembolic and hemorrhagic complica-
tions to the patient’s INR, we didn’t specifically relate the inci-
dence of the complication to the INR, but that would be something
that worth looking at. As far as decreasing the targeted INR is
concerned, despite the fact that we have decreased the INR in our
institution, this has not resulted in an increase in thromboembolic
rates; in fact, it has still dropped to a small extent. Therefore, at the
present time we feel that our current target INRs are safe.
Dr Kit V. Arom (Minneapolis, Minn). I rise to congratulate the
group from Charleston for their excellent long-term follow-ups,
particularly with 98% completed. We, too, in Minneapolis, after
Demetre Nicoloff implanted the first valve in 1977, have followed
these people up to 20 years. At that time with 95.4% complete
(21,342 patient years), we had 3937 patients available for the
study. About 1300 of the patients were dead at that time or
approximately one third of them.
The causes of death were 4.5% valve-related, 4% related to
anticoagulation. The rest of them died from ongoing atherosclero-
sis and heart failure (48%). Linearized rate (percent per patient-
year) included 1.24 for thromboembolism (TE), 1.00 for bleeding,
0.1 for perivalvular leak, 0.18 for prosthetic endocarditis, and
valve thrombosis was 0.09.
If we translate this into actuarial analysis, we obtained results
similar to yours, except in 2 areas. One is that at the end of 20
years our aortic valve had better survival rate than the mitral valve,
being about 44%, comparing with about 33% for the mitral valve.
And the other area was the incidence free from bleeding and
TE. There was about 82% incidence free from bleeding and 70%
free from TE. If I remember correctly, this is quite different than
yours, which it is about 60%.
We did lower the intensity of anticoagulation in 1985 by
keeping the INR between 1.8 and 2.5 for AVR, 2.5 and 3.2 for
MVR.
Dr Trento has suggested lowering intensity of anticoagulation,
which I agree with. At the present time we still using a slightly
lower intensity than what you just described, and I think this could
be the reason why we see a slightly better TE and bleeding rate.
Dr Ikonomidis. How did you conduct the follow-up on your
patients?
Dr Arom. Our follow-up is not quite as good as yours, which
is being done yearly. We hope, however, that we can use the same
approach that you do. In 1985, we also instructed the cardiologist
and family physician to stop using prothrombin values and to have
the INR strictly within the range that I have mentioned. I really
believe that this approach has contributed to our recent outcomes.
Dr Ikonomidis. The less aggressive warfarin dosing that you
described may help address your improved freedom from TE and
bleeding compared with our series. In addition, conducting fol-
low-up over longer time intervals may cause patients to forget
some events, effectively increasing the documented freedom from
TE and bleeding complications.
As for addressing the flip in terms of aortic and mitral valve
survival, I think that this discrepancy may reflect inherent differ-
Appendix. Variables examined for association with
operative mortality and late death
Operative mortality Late survival
Aortic valves Aortic valves
Gender Gender
Age at operation Age at operation
Body surface area Year of surgery
Year of surgery Race
Race Valve size  21 mm
Valve size 19 mm Effective orifice area 2.59
CABG 3 or more vessels Effective orifice area index
Reoperation Associated CABG
Preoperative NYHA class IV Reoperation
Lesion (aortic stenosis) Preoperative NYHA class III or IV
Lesion (aortic stenosis)
Mitral valves Mitral valves
Gender Gender
Age at operation Age at operation
Body surface area Year of surgery
Year of surgery Race
Race Valve size
Valve size 19 mm Associated CABG
CABG 3 or more vessels Reoperation
Reoperation Preoperative NYHA class III or IV
Preoperative NYHA class IV Lesion (mitral insufficiency)
Lesion (mitral insufficiency) Ischemic etiology
Ischemic etiology
NYHA, New York Heart Association; CABG, coronary artery bypass graft-
ing.
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ences in the population as they relate to severity of comorbid
factors such as hypertension, left ventricular hypertrophy, and
perhaps even compliance with medications.
Dr W. R. Eric Jamieson (Vancouver, British Columbia, Can-
ada). Congratulations on an excellent study. I just have 2 short
questions. You shared with us your linearized occurrence rates for
aortic and mitral valves. Could you share with us the linearized
rates for major embolisms, including Reversible Ischemic Neuro-
logic Deficits, and comment also on early and late events, because
many patient mechanical populations can have major events in the
first 30 days.
My second question is related: have you looked at actual versus
actuarial freedoms when you assess the composites of complica-
tions, morbidity, mortality, and reoperation, which are probably
better parameters when you are counseling patients to have a
mechanical or any prosthesis?
Dr Ikonomidis. I am sorry, Dr Jamieson, can you repeat the
second question?
Dr Jamieson. The concept of using actual freedoms compared
with actuarial freedoms, which are better parameters to use when
counseling patients as to which prosthesis they should have.
Dr Ikonomidis. All of the nondeath outcomes were analyzed
by cumulative incidence analysis. I did not include them here in
this presentation for purposes of simplicity but in all end points
measured, the cumulative incidence curves were all shifted upward
compared with the actuarial freedom curves, as one would expect.
With regard to neurologic events, approximately one third were
early and then the remaining two thirds occurred later on.
Dr Mohammed A. Quader (Cleveland, Ohio). Congratula-
tions on your excellent presentation of this valuable data. I would
like to ask you a question about the use of 19-mm valves. Fifteen
percent of the patients had the 19-mm valve placed, and multivar-
iate analysis has shown that there is an increased risk of death with
that. Has there been a trend toward not using this valve more
frequently in the recent past?
Also, have you looked for patient-prosthesis mismatch in that
group of patients?
Dr Ikonomidis. We have trended toward not using 19-mm
valves as much as possible. As far as patient-prosthesis mismatch
is concerned, neither EOA nor EOA index were found to be
multivariate predictors of death.
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